22 research outputs found
BLOOM: A 176B-Parameter Open-Access Multilingual Language Model
Large language models (LLMs) have been shown to be able to perform new tasks
based on a few demonstrations or natural language instructions. While these
capabilities have led to widespread adoption, most LLMs are developed by
resource-rich organizations and are frequently kept from the public. As a step
towards democratizing this powerful technology, we present BLOOM, a
176B-parameter open-access language model designed and built thanks to a
collaboration of hundreds of researchers. BLOOM is a decoder-only Transformer
language model that was trained on the ROOTS corpus, a dataset comprising
hundreds of sources in 46 natural and 13 programming languages (59 in total).
We find that BLOOM achieves competitive performance on a wide variety of
benchmarks, with stronger results after undergoing multitask prompted
finetuning. To facilitate future research and applications using LLMs, we
publicly release our models and code under the Responsible AI License
Realâlife activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program
International audienceEribulin mesylate (EM) was recently approved for metastatic breast cancer (MBC) chemotherapy (CT) in late lines by the FDA, with debated results in second line. We evaluated outcomes in breast cancer patients receiving EM as second, third and fourth line in a national real-life cohort of 16,703 consecutive MBC patients initiating their first metastatic therapeutic line between 2008 and 2014. Primary and secondary objectives were overall survival (OS) and progression-free survival (PFS). An imbalance was seen for HER2+ tumors and concomitant anti-HER2 targeted therapies use, we thus performed a subanalysis in HER2- patients. PFS and OS were significantly better in EM patients in third and fourth lines, compared to "Other chemotherapies" patients (PFS: 4.14 vs. 3.02âmonths, pâ=â0.0010; 3.61 vs. 2.53âmonths, pâ=â0.0102, third and fourth-line; OS: 11.27 vs. 7.65âmonths, pâ=â0.0001; 10.91 vs. 5.95âmonths, pâ<â0.0001, third and fourth-line). No significant difference was reported in second-line (PFS: 5.06 vs. 4.14âmonths, pâ=â0.1171; OS: 13.99 vs. 11.66âmonths, pâ=â0.151). Among HER2- patients, a significant difference was seen for all lines, including 2nd-line (PFS: 4.57 vs. 3.91âmonths, pâ=â0.0379; OS: 14.98 vs. 10.51âmonths, pâ=â0.0113). In this large real-world database, HER2-negative MBC patients receiving EM in second or later CT line presented significantly better PFS and OS. This difference disappeared in second line in the overall population, probably because of the imbalance in HER2-targeted treatments use. Our results mirror those of the published randomized trials. The effect of anti-HER2 therapies addition in this setting still needs to be defined
Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study
International audienc
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study
Everolimus is the first oral targeted therapy widely used in advanced HR+/HER2â breast cancer. We sought to evaluate the impact of everolimus-based therapy on overall survival in the ESME-MBC database, a national metastatic breast cancer cohort that collects retrospective data using clinical trial-like methodology including quality assessments. We compared 1693 patients having received everolimus to 5928 patients not exposed to everolimus in the same period. Overall survival was evaluated according to treatment line, and a propensity score with the inverse probability of treatment weighting method was built to adjust for differences between groups. Crude and landmark overall survival analyses were all compatible with a benefit from everolimus-based therapy. Adjusted hazard ratios for overall survival were 0.34 (95% CI: 0.16â0.72, p = 0.0054), 0.34 (95% CI: 0.22â0.52, p < 0.0001), and 0.23 (95% CI: 0.14â0.36, p < 0.0001) for patients treated with everolimus in line 1, 2, and 3 and beyond, respectively. No clinically relevant benefit on progression-free survival was observed. Causes for everolimus discontinuation were progressive disease (56.2%), adverse events (27.7%), and other miscellaneous reasons. Despite the limitations inherent to such retrospective studies, these results suggest that adding everolimus-based therapy to the therapeutic sequences in patients with advanced HR+/HER2â breast cancer may favorably affect overall survival
Real-world evidence of the management and prognosis of young women (â©œ40âyears) with de novo metastatic breast cancer
International audienceBackground: Breast cancer (BC) in young women merits a specific approach given the associated fertility, genetic and psychosocial issues. De novo metastatic breast cancer (MBC) in young women is an even more serious condition, with limited data available. Methods: We evaluated management of women aged â©œ40âyears with de novo MBC in a real-life national multicentre cohort of 22,463 patients treated between 2008 and 2016 (NCT0327531). Our primary objective was to compare overall survival (OS) in young women versus women aged 41â69âyears. The secondary objectives were to compare first-line progression-free survival (PFS1) and to describe treatment patterns. Results: Of the 4524 women included, 598 (13%) were â©œ40âyears. Median age at MBC diagnosis was 36âyears (rangeâ=â20â40). Compared with women aged 41â69âyears, young women had more grade III tumours (49% versus 35.7%, pâ<â0.0001), human epidermal growth factor receptor 2 amplified (HER2+) disease (34.6% versus 26.4%, pâ<â0.0001) and HRâ/HER2â disease known as âtriple negative breast cancerâ (TNBC) (17.1% versus 12.7%, pâ<â0.0001). BRCA testing was performed for 260 young women, with a BRCA1/2 mutation in 44 (17% of those tested) In young HR+/HER2â patients, chemotherapy (CT) was given as the frontline treatment more frequently compared with older ones (89.6% versus 68.8%, respectively, pâ<â0.0001). After median follow-up of 49.7âmonths (95% confidence interval, CIâ=â48.0â51.7), the median OS of young women was 58.5âmonths, 20.7âmonths and not attained in HR+/HER2â, TNBC and HER2+ subgroups, respectively. After adjustment for histological subtype, tumour grade, and number and type of metastasis, young women had significantly better OS compared with older ones, except for the TNBC subgroup, for which the outcome was similar. PFS1 was statistically different only in the TNBC subgroup, with 7.8âmonths for young women and 6.3âmonths for older women ( pâ=â0.0015). Conclusion: De novo MBC affects a significant proportion of young women. A subgroup of these patients achieves long OS and merits multidisciplinary care
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort
International audienceYoung age is a poor prognostic factor in early stage breast cancer (BC) but its value is less established in metastatic BC (MBC). We evaluated the impact of age at MBC diagnosis on overall survival (OS) across three age groups (Â 60 years(y))